Summary & Overview
HCPCS Q4126: Dermal Substitute (per sq cm) Add-on for Skin Grafting
HCPCS Level II code Q4126 represents billing for dermal substitute products (Memoderm, Dermaspan, Tranzgraft, Integuply) reported per square centimeter as an add-on to a primary surgical procedure. These products are used in skin grafting and wound reconstruction to support dermal regeneration and improve wound healing outcomes. Nationally, accurate reporting of add-on product codes like Q4126 affects procedure-level costing, device utilization tracking, and payment adjudication across public and private payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for dermal substitute use, coding guidance on the add-on nature of the product, typical sites of service where the product is used, and operational considerations for billing and documentation. The publication summarizes benchmark topics such as common modifier usage, payer coverage patterns, and where to expect policy variability.
This summary is intended for billing managers, clinicians involved in wound care and reconstructive procedures, and policy analysts responsible for device reimbursement and outpatient surgical coding. Data not available in the input will be noted where applicable in the full publication.
Billing Code Overview
HCPCS Level II code Q4126 describes an add-on skin graft matrix product — specifically Memoderm, Dermaspan, Tranzgraft, or Integuply — billed per square centimeter and reported in addition to a primary procedure.
Service type: Dermal substitute/skin graft matrix product (add-on)
Typical site of service: Outpatient surgical settings, hospital outpatient departments, ambulatory surgical centers, and other procedural care locations where skin grafting or wound reconstruction is performed.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a full-thickness lower-leg wound following excision of chronic non-healing ulceration is evaluated in the outpatient surgical clinic. After debridement and assessment, the surgical team elects to apply an advanced dermal regenerative matrix product such as Q4126 (Memoderm, DermaSpan, Tranzgraft, or Integuply) to provide a scaffold for dermal regeneration prior to or in conjunction with split-thickness skin grafting. The workflow includes pre-procedure consent, measurement of the wound surface area in square centimeters, procurement and preparation of the dermal matrix per manufacturer instructions in the procedure area (office procedure room, ambulatory surgery center, or inpatient operating room), secure placement of the material over the wound bed, and fixation with sutures, staples, or dressing as clinically indicated. Post-procedure care includes dressing changes, off-loading, and serial follow-up to monitor integration and re-epithelialization. Documentation includes product name, square centimeters applied, indication for use, wound measurements, debridement details, and concurrent procedures such as grafting or wound closure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; default submission | Use when no special circumstances or modifier apply to the service. |
| 22 | Increased procedural services | Use when the dermal matrix application required substantially greater effort, time, or complexity than typical and documentation supports unusual work.